Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis

J P Donohue1, E P Fox, S D Williams

  • 1Indiana University Medical Center, Department of Urology, Indianapolis 46202-5250.

World Journal of Urology
|January 1, 1994
PubMed
Summary

For metastatic testis cancer patients with refractory tumors, post-operative chemotherapy after retroperitoneal lymph node dissection (RPLND) surgery does not improve outcomes. Complete tumor resection is the primary factor for long-term cure in these challenging cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Long-term toxicity of cisplatin in germ-cell tumor survivors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Utilization of sperm banking and barriers to its use in testicular cancer patients.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2015

Area of Science:

  • Oncology
  • Surgical Oncology
  • Chemotherapy Research

Background:

  • Metastatic testis cancer treatment often involves chemotherapy followed by surgery for residual disease.
  • Post-chemotherapy surgery, specifically retroperitoneal lymph node dissection (RPLND), is crucial for localized, resectable tumors after initial chemotherapy.
  • Patients with refractory tumors who have undergone both primary and salvage chemotherapy present a unique challenge for surgical management and adjuvant therapy decisions.

Purpose of the Study:

  • To evaluate the efficacy of repeat salvage chemotherapy following RPLND surgery in patients with metastatic testis cancer and refractory tumors.
  • To determine if adjuvant chemotherapy improves cure rates in patients who have already received salvage chemotherapy and undergone RPLND.
  • To identify prognostic factors, such as completeness of resection, influencing long-term outcomes in this patient cohort.

Related Experiment Videos

Main Methods:

  • Retrospective analysis of 91 patients with metastatic testis cancer who underwent RPLND after salvage chemotherapy.
  • Categorization of patients based on completeness of surgical resection (completely vs. incompletely resected).
  • Comparison of outcomes (no evidence of disease rates, disease-specific mortality) between patients who received repeat post-operative salvage chemotherapy and those who did not, particularly within the completely resected group.

Main Results:

  • Approximately 55% of patients undergoing RPLND after salvage chemotherapy had persistent cancer in the resected specimen.
  • In patients with complete resections (n=53), repeat post-operative salvage chemotherapy did not significantly improve rates of remaining no evidence of disease (NED) (36% with chemotherapy vs. 43% without).
  • Disease-specific mortality was similar between the groups receiving and not receiving repeat salvage chemotherapy (12 deaths in each group).

Conclusions:

  • There is no data to support the routine use of repeat salvage chemotherapy post-operatively in patients with completely resected metastatic testis cancer after prior salvage chemotherapy.
  • The completeness of surgical resection during RPLND is a more critical determinant of long-term cure than adjuvant chemotherapy in this patient population.
  • Treatment decisions for patients with refractory metastatic testis cancer should prioritize achieving complete surgical resection.